Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 233 | 32 | 200 |
| Samples | 127 | 24 | 102 |
| Peptides | 100 | 15 | 88 |
Function
LAIR2 · Leukocyte associated immunoglobulin like receptor 2
The protein encoded by this gene is a member of the immunoglobulin superfamily. It was identified by its similarity to leukocyte-associated immunoglobulin-like receptor 1, a membrane-bound receptor that modulates innate immune response. The protein encoded by this locus is a soluble receptor that may play roles in both inhibition of collagen-induced platelet aggregation and vessel formation during placental implantation. This gene maps to a region of 19q13.4, termed the leukocyte receptor cluster, which contains 29 genes in the immunoglobulin superfamily. Alternatively spliced transcript variants have been described for this gene. [provided by RefSeq, Sep 2013].
Isoforms & Proteins
3 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000301202 | Q6ISS4 | 130 | 91 |
| ENST00000351841 | Q6ISS4-2 | 102 | 78 |
| ENST00000622161 | A0A087X1V4* | 1 | 1 |
Gene Properties
Recurrent Mutations
All 91 amino-acid changes on canonical ENST00000301202 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in LAIR2 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in LAIR2 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Oral Cavity Carcinoma | 2/54 4% | 0/0 0% |
| T-Lymphoblastic Leukemia | 1/40 2% | 0/0 0% |
| Glioblastoma | 2/98 2% | 0/0 0% |
| Squamous Cell Lung Carcinoma | 6/57 11% | 6/810 1% |
| Melanoma | 2/210 1% | 25/1899 1% |
| Other Solid Cancers | 1/94 1% | 13/1515 1% |
| Cervical Carcinoma | 1/35 3% | 2/422 0% |
| Ewings Sarcoma | 2/63 3% | 0/262 0% |
| Non-Small Cell Lung Carcinoma | 0/304 0% | 10/1390 1% |
| Small Cell Lung Carcinoma | 0/9 0% | 4/752 1% |
| Endometrial Carcinoma | 0/42 0% | 2/612 0% |
| Plasma Cell Myeloma | 0/44 0% | 1/305 0% |
| Neuroendocrine Tumour | 2/154 1% | 0/577 0% |
| Gastric Carcinoma | 0/74 0% | 5/1809 0% |
| Medulloblastoma | 0/0 0% | 1/450 0% |
| Breast Carcinoma | 2/144 1% | 5/3264 0% |
| Colorectal Carcinoma | 0/143 0% | 7/3239 0% |
| Biliary Tract Carcinoma | 0/54 0% | 2/950 0% |
| Bladder Carcinoma | 0/58 0% | 2/956 0% |
| Hepatocellular Carcinoma | 1/46 2% | 3/2210 0% |
| Glioma | 2/52 4% | 2/2127 0% |
| Kidney Carcinoma | 0/85 0% | 3/1862 0% |
| Esophageal Carcinoma | 0/23 0% | 1/769 0% |
| Head and Neck Carcinoma | 0/85 0% | 2/1574 0% |
| Prostate Carcinoma | 0/13 0% | 2/2105 0% |
| Ovarian Carcinoma | 0/109 0% | 1/998 0% |
| Neuroblastoma | 0/87 0% | 1/1331 0% |
| Thyroid Gland Carcinoma | 0/45 0% | 1/1592 0% |
| Pancreatic Carcinoma | 0/89 0% | 1/1611 0% |
| B-Lymphoblastic Leukemia | 0/55 0% | 1/2640 0% |
Mutation Distribution
Where LAIR2 is mutated · all tissues, split by cell line vs tissue
How many mutations in LAIR2 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 29 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 233 mutations in LAIR2
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|